Dr michael har noy

Dr. Michael Har-Noy Reports Remarkable Survival Data In Breast Cancer Patients

In a preliminary Phase I/II study of AlloStimTM in patients with various solid metastatic tumors, Dr. Michael Har-Noy reported encouraging survival data. Out of the 42 patients studied, Dr. Michael Har-Noy said that the subset of five HER2+ breast cancer patients had a median survival of 416 days – markedly longer than the predicted survival of 60 days or less. These five HER2+ patients had high levels of interleukin 12 – an apparent marker for a positive response. Dr. Michael Har-Noy intends to conduct a pivotal Phase II/III trial of AlloStim TM in metastatic breast cancer patients.

Dr. Michael Har-Noy Reports Remission of Lung Cancer In Dog Treated With CRCL Dr. Michael Har-Noy reports that a 12 year old Great Dane with bronchoalveolar adenocarcinoma was treated with a chaperone-rich cell lysate (CRCL) vaccine processed from the dog’s tumor. Dr. Michael Har-Noy indicates that the expected survival of the dog was six to 27 days. After treatment, the dog remained cancer-free for 44 weeks, when a relapse occurred.

The dog was euthanized at about 50 weeks post-treatment. Dr. Michael Har-Noy concludes that CRCL vaccine is a safe and very effective adjuvant treatment for canine tumors.

Dr. Michael Har-Noy Is Conducting A Compassionate Use Program In Thailand Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd. is running a Compassionate Use program in Bangkok, Thailand. Dr. Michael Har-Noy says that this program is being integrated into Phase I/II trials of the CRCL-AlloVaxTM compound. The Compassionate Use program allows patients who have exhausted other treatment options to benefit from these unique products. Dr. Michael Har-Noy will soon be conducting pivotal Phase II/III trials involving breast and colon cancer patients. The CRCL-AlloVaxTM product may also have potential benefit in the treatment of HIV patients.

Dr. Michael Har-Noy Says RECIST Criteria Inadequately Evaluates Tumor Response To Immunologic Treatment Dr. Michael Har-Noy says that conventional RECIST criteria are not applicable to immunologic cancer treatments. RECIST criteria dictate that a partial response to therapy means that a 30% decrease in tumor size from baseline sum of the longest diameter must be observed. Dr. Michael Har-Noy says that after immune treatment, metastatic tumors usually actually swell secondary to the inflammatory response and may appear larger on imaging studies. However, subsequent biopsies of these enlarged lesions usually show cell death and fibrosis. Dr. Michael Har-Noy says that as immunologic treatments become better understood, more relevant response criteria will be developed.

Thank You https://www.smore.com/qump-michael-har-noy